Singapore, Sep 02, 2010: The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded a $153 million contract to California-based Cellerant Therapeutics, to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body’s cells, the type of radiation that would come from a nuclear blast.
Under the contract, the company will continue development of a medication called CLT-008 that uses a special kind of cells called myeloid progenitor cells. The medicine potentially could be used to treat the illness known as neutropenia, an abnormally low number of white blood cells. In addition, the treatment potentially could be used for other blood disorders and complications of cancer, in which blood cells and platelets need to be replenished.
The body has progenitor cells that can grow into any kind of blood cell the body needs. CLT-008 is being developed to support and add to the patient’s own progenitor cells.
The contract to Cellerant is for approximately $63.2 million in the first two years. The contract can be extended annually for up to three years for an additional $89.9 million.
The contract is a follow on from a previous contract between BARDA and Cellerant which supported advanced research and development of this cell-based treatment. Under the new contract, the company will conduct additional studies and validate their manufacturing process in order to apply for U.S. Food and Drug Administration licensure of this method of treating neutropenia.
| 
Comment on this article
